Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats

European Journal of Pharmacology

Volumn 337, Issue 1, 1997, Pages 27-34

  Paronis, Carol A ^a   Woods, James H ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

3H DAMGO ( 3H D Ala2,N Me Phe4,Gly5 ol enkephalin; Analgesia; Clocinnamox; Morphine; Opioid receptor binding; Rat

Indexed keywords

CLOCINNAMOX; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; MORPHINE; OPIATE ANTAGONIST;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANALGESICS, OPIOID; ANIMALS; CINNAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALINS; FEMALE; KINETICS; MEMBRANES; MORPHINE; MORPHINE DERIVATIVES; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; TIME FACTORS;

EID: 0030828663     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01296-X     Document Type: Article

References (28)

1. Aceto M.D., Bowman E.R., May E.L., Harris L.S., Woods J.H., Smith C.B., Medzihradsky F., Jacobson A.E. Very long-lasting narcotic antagonists: The 14β-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives. Arzneim. Forsch. Drug Res. 39:1989;570-575.
2. Adams J.U., Andrews J.S., Hiller J.M., Simon E.J., Holtzman S.G. Effects of stress and β-funaltrexamine on morphine analgesia and opioid binding in rats. Life Sci. 41:1987;2835-2844.
3. Adams J.U., Paronis C.A., Holtzman S.G. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using β-funaltrexamine. J. Pharmacol. Exp. Ther. 255:1990;1027-1032.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
5. Burke T.F., Woods J.H., Lewis J.W., Medzihradsky F. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J. Pharmacol. Exp. Ther. 271:1994;715-721.
6. Chan K., Brodsky M., Davis T., Franklin S., Inturrisi C.E., Yoburn B.C. The effects of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA. Eur. J. Pharmacol. 287:1995;135-143.
7. Clark M.J., Carter B.D., Medzihradsky F. Selectivity of ligand binding to opioid receptors in brain membranes from the rat, monkey and guinea pig. Eur. J. Pharmacol. 148:1988;343-351.
8. Comer S.D., Burke T.F., Lewis J.W., Woods J.H. Clocinnamox: A novel, systemically-active irreversible opioid antagonist. J. Pharmacol. Exp. Ther. 262:1992;1051-1056.
9. Dykstra L.A., Gmerek D.E., Winger G., Woods J.H. Kappa opioids in rhesus monkeys. II. Analysis of the antagonistic actions of quadazocine and β-funaltrexamine. J. Pharmacol. Exp. Ther. 242:1987;421-427.
10. Horan P., Taylor J., Yamamura H.I., Porreca F. Extremely long-lasting antagonist actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J. Pharmacol. Exp. Ther. 260:1992;1237-1243.
11. Jewett D.J., Woods J.H. Nor-binaltorphimine: An ultra-long acting kappa-opioid antagonist in pigeons. Behav. Pharm. 6:1995;815-821.
12. Jiang Q., Sebastian A., Archer S., Bidlack J.M. 5β-methyl-14β-(p-nitrocinnamoylamino)-7,8-dihydomorphinone and its corresponding n-cyclopropylmethyl analog, n-cyclopropylmethylnor-5β-methyl-14β-(p-nitrocinnamoylamino)-7,8- dihydomorphinone: Mu-selective irreversible opioid antagonists. J. Pharmacol. Exp. Ther. 268:1994;1107-1113.
13. Jones D.N.C., Holtzman S.G. Long-term k-opioid receptor blockade following nor-binaltorphimine. Eur. J. Pharmacol. 215:1992;345-348.
14. Lewis J., Smith C., McCarthy P., Walter D., Kobylecki R., Myers M., Haynes A., Lewis C., Waltham K. New 14-aminomorphinones and codeinones. NIDA Res. Monogr. 90:1988;136-143.
15. 3H ]β-funaltrexamine Mol. Pharmacol. 32:1987;321-329.
16. Liu-Chen L.-Y., Li S., Wheeler-Aceto H., Cowan A. Effects of intracerebroventricular β-funaltrexamine on mu and delta opioid receptors in the rat: Dichotomy between binding and antinociception. Eur. J. Pharmacol. 203:1991;195-202.
17. Liu-Chen L.-Y., Yang H.-H., Li S., Adams J.U. Effect of intracerebroventricular β-funaltrexamine on mu opioid receptors in the rat brain: Consideration of binding condition. J. Pharmacol. Exp. Ther. 273:1995;1047-1056.
18. Mansour A., Fox C.A., Akil H., Watson S.J. Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications. Trends Neurosci. 18:1995;22-29.
19. Martin T.J., Dworkin S.I., Smith J.E. Alkylation of mu opioid receptors by β-funaltrexamine in vivo: Comparison of the effects on in situ binding and heroin self-administration in rats. J. Pharmacol. Exp. Ther. 272:1995;1131-1140.
20. Standifer K.M., Chien C.-C., Wahlestedt C., Brown G.P., Pasternak G.W. Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor. Neuron. 12:1994;805-810.
21. Tam S.W., Liu-Chen L.-Y. Reversible and irreversible binding of β-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes. J. Pharmacol. Exp. Ther. 239:1986;351-357.
22. Walker E.A. Etonitazene analgesia in rats: Antagonism, tolerance and cross-tolerance. NIDA Res. Monogr. 174:1997;73.
23. 2 analysis in rats treated with either clocinnamox or morphine. Psychopharmacology. 125:1996;113-119.
24. Ward S.J., Portoghese P.S., Takemori A.E. Pharmacological profiles of β-funaltrexamine (β-FNA) and β-chlornaltrexamine (β-CNA) on the mouse vas deferens preparation. Eur. J. Pharmacol. 80:1982;377-384.
25. Ward S.J., Fries D.S., Larson D.L., Portoghese P.S., Takemori A.E. Opioid receptor binding characteristics of the non-equilibrium mu-antagonist, β-funaltrexamine (β-FNA). Eur. J. Pharmacol. 107:1985;323-330.
26. 3H ]clocinnamox binding in mouse brain membranes Analgesia. 1:1995;874-877.
27. Zernig G., Burke T., Lewis J.W., Woods J.H. Mechanism of clocinnamox blockade of opioid receptors: Evidence from in vitro and ex vivo binding and behavioral assays. J. Pharmacol. Exp. Ther. 279:1996;23-31.
28. Zernig G., Butelman E.R., Lewis J.W., Walker E.A., Woods J.H. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J. Pharmacol. Exp. Ther. 269:1994;57-65.